QRS interval widening appears to be highly specific for the diagnosis of hyperkalemia in patients with end-stage kidney disease. ECG changes, in general, have poor sensitivities for hyperkalemia in ...

NEW YORK--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ Guard TM, an FDA Breakthrough Device ...

AliveCor has received approval from the Food and Drug Administration (FDA) to develop a non-invasive method of detecting high blood potassium levels. The startup, which chiefly focuses on monitoring ...

In patients with severe hyperkalemia, the Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality. Among patients with severe hyperkalemia ...

NEW YORK, January 07, 2025--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, has announced that it has received Breakthrough Device Designation by the U.S. Food and Drug ...

Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...

The treatment of hyperkalemia can require urgent measures. Fortunately, it can usually be preemptively managed before serum K+ values become dangerously high. The urgency with which therapy is ...